A detailed history of Hollencrest Capital Management transactions in Biogen Inc. stock. As of the latest transaction made, Hollencrest Capital Management holds 13 shares of BIIB stock, worth $2,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13
Previous 13 -0.0%
Holding current value
$2,259
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

SELL
$256.56 - $292.34 $51,312 - $58,467
-200 Reduced 93.9%
13 $3,000
Q4 2022

Feb 06, 2023

BUY
$252.44 - $306.72 $53,769 - $65,331
213 New
213 $58,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Hollencrest Capital Management Portfolio

Follow Hollencrest Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hollencrest Capital Management with notifications on news.